JCO Article Insights: LEAP-010 Study in Recurrent/Metastatic Head and Neck Cancer
Episode Description
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study."

























